Forty-one patients (34%) were found to have epidermal growth factor receptor (EGFR)-mutated lung cancer, while 65 had wild type EGFR tumors (54%); mutational status was unknown in the remaining 14 patients (12%). Here, EGFR is linked to lung carcinoma.